These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 24244025)

  • 1. Differences in the phenotype, cytokine gene expression profiles, and in vivo alloreactivity of T cells mobilized with plerixafor compared with G-CSF.
    Lundqvist A; Smith AL; Takahashi Y; Wong S; Bahceci E; Cook L; Ramos C; Tawab A; McCoy JP; Read EJ; Khuu HM; Bolan CD; Joo J; Geller N; Leitman SF; Calandra G; Dunbar C; Kurlander R; Childs RW
    J Immunol; 2013 Dec; 191(12):6241-9. PubMed ID: 24244025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of donor hematopoietic cells mobilized with G-CSF and plerixafor on murine acute graft-versus-host-disease.
    Arbez J; Saas P; Lamarthée B; Malard F; Couturier M; Mohty M; Gaugler B
    Cytotherapy; 2015 Jul; 17(7):948-55. PubMed ID: 25813681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accelerated lymphocyte reconstitution and long-term recovery after transplantation of lentiviral-transduced rhesus CD34+ cells mobilized by G-CSF and plerixafor.
    Uchida N; Bonifacino A; Krouse AE; Metzger ME; Csako G; Lee-Stroka A; Fasano RM; Leitman SF; Mattapallil JJ; Hsieh MM; Tisdale JF; Donahue RE
    Exp Hematol; 2011 Jul; 39(7):795-805. PubMed ID: 21549175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superior long-term repopulating capacity of G-CSF+plerixafor-mobilized blood: implications for stem cell gene therapy by studies in the Hbb(th-3) mouse model.
    Psatha N; Sgouramali E; Gkountis A; Siametis A; Baliakas P; Constantinou V; Athanasiou E; Arsenakis M; Anagnostopoulos A; Papayannopoulou T; Stamatoyannopoulos G; Yannaki E
    Hum Gene Ther Methods; 2014 Dec; 25(6):317-27. PubMed ID: 25333506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.
    Girbl T; Lunzer V; Greil R; Namberger K; Hartmann TN
    Transfusion; 2014 Sep; 54(9):2325-35. PubMed ID: 24673458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures.
    Donahue RE; Jin P; Bonifacino AC; Metzger ME; Ren J; Wang E; Stroncek DF
    Blood; 2009 Sep; 114(12):2530-41. PubMed ID: 19602709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in Cellular Composition of Peripheral Blood Stem Cell Grafts from Healthy Stem Cell Donors Mobilized with Either Granulocyte Colony-Stimulating Factor (G-CSF) Alone or G-CSF and Plerixafor.
    Teipel R; Oelschlägel U; Wetzko K; Schmiedgen M; Kramer M; Rücker-Braun E; Hölig K; von Bonin M; Heidrich K; Fuchs A; Ordemann R; Kroschinsky F; Bornhäuser M; Hütter G; Schmidt H; Ehninger G; Schetelig J; Heidenreich F
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2171-2177. PubMed ID: 29935214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation.
    MacDonald KP; Rowe V; Filippich C; Thomas R; Clouston AD; Welply JK; Hart DN; Ferrara JL; Hill GR
    Blood; 2003 Mar; 101(5):2033-42. PubMed ID: 12393418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
    Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the content and subpopulations of CD3 and CD34 positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors.
    Hassan HT; Stockschläder M; Schleimer B; Krüger W; Zander AR
    Transpl Immunol; 1996 Dec; 4(4):319-23. PubMed ID: 8972563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic stem cell mobilization for gene therapy: superior mobilization by the combination of granulocyte-colony stimulating factor plus plerixafor in patients with β-thalassemia major.
    Yannaki E; Karponi G; Zervou F; Constantinou V; Bouinta A; Tachynopoulou V; Kotta K; Jonlin E; Papayannopoulou T; Anagnostopoulos A; Stamatoyannopoulos G
    Hum Gene Ther; 2013 Oct; 24(10):852-60. PubMed ID: 24001178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Single-Dose Plerixafor as an Adjunct to Granulocyte Colony-Stimulating Factor-Based Peripheral Blood Stem Cell Mobilization on the Graft Composition and Outcome for T Cell-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide: A Comparative Study.
    Jaiswal SR; Bhakuni P; Joy A; Murli N; Bharadwaj P; Zaman S; Nedunchezian M; Chakrabarti S
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):542-548. PubMed ID: 29191663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
    Steinberg M; Silva M
    Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor.
    Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E
    Transfusion; 2012 Aug; 52(8):1785-91. PubMed ID: 22304442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease.
    Pan L; Teshima T; Hill GR; Bungard D; Brinson YS; Reddy VS; Cooke KR; Ferrara JL
    Blood; 1999 Jun; 93(12):4071-8. PubMed ID: 10361103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modification of T cell responses by stem cell mobilization requires direct signaling of the T cell by G-CSF and IL-10.
    MacDonald KP; Le Texier L; Zhang P; Morris H; Kuns RD; Lineburg KE; Leveque L; Don AL; Markey KA; Vuckovic S; Bagger FO; Boyle GM; Blazar BR; Hill GR
    J Immunol; 2014 Apr; 192(7):3180-9. PubMed ID: 24585878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of peripheral blood stem cell grafts mobilized by granulocyte colony-stimulating factor and plerixafor compared with granulocyte colony-stimulating factor alone.
    Gaugler B; Arbez J; Legouill S; Tiberghien P; Moreau P; Derenne S; Saas P; Mohty M
    Cytotherapy; 2013 Jul; 15(7):861-8. PubMed ID: 23731764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Machine learning-based scoring models to predict hematopoietic stem cell mobilization in allogeneic donors.
    Xiang J; Shi M; Fiala MA; Gao F; Rettig MP; Uy GL; Schroeder MA; Weilbaecher KN; Stockerl-Goldstein KE; Mollah S; DiPersio JF
    Blood Adv; 2022 Apr; 6(7):1991-2000. PubMed ID: 34555850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced antileukemic activity of allogeneic peripheral blood progenitor cell transplants following donor treatment with the combination of granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) in a murine transplantation model.
    Hartung G; Zeis M; Glass B; Dreger P; Steinmann J; Schmitz N; Uharek L
    Bone Marrow Transplant; 2003 Jul; 32(1):49-56. PubMed ID: 12815478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation.
    Gattillo S; Marktel S; Rizzo L; Malato S; Malabarba L; Coppola M; Assanelli A; Milani R; De Freitas T; Corti C; Bellio L; Ciceri F
    Transfusion; 2015 Aug; 55(8):1993-2000. PubMed ID: 25721167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.